Brain Regeneration Technology soared 328.4%, triggering a trading halt at $67.09, hitting an all-time high. The cumulative increase this year has exceeded 51,507%.
Brain Regeneration Technology is a holding company incorporated in the Cayman Islands in October 2014, primarily operated through its Hong Kong subsidiary, with a total of 12 employees. The company focuses on researching, developing, and commercializing traditional Chinese medicines for the treatment of neurocognitive disorders and degenerative diseases, particularly in the directions of ADHD (Attention-Deficit/Hyperactivity Disorder) and ASD (Autism Spectrum Disorder).
However, as of the end of June 2024, the company has not generated any revenue from the sale of any products, and its revenue was zero from fiscal years 2021 to 2024.
In its fiscal 2024 earnings report, Brain Regeneration Technology stated: "It may never be profitable" and "there are uncertainties about its ability to continue as a going concern."
$RGC 
